Pharma R&D Efficiency: Mid-Sized Companies Excel

Datamonitor Healthcare's recent review of R&D efficiency using new product launch success rates as a proxy shows that Mid Pharma companies outperform Big Pharma and Japan Pharma firms, thanks to multiple blockbuster drugs. The first in a two-part series evaluating R&D productivity.

Development of innovative pharmaceuticals is a time-consuming and costly process. Budget cuts, R&D facility closures as a result of industry consolidation, pressure from investors to deliver returns and other economic conditions have put a strain on the ability to fund the development of new drugs. There is also increased pressure to develop products in the most efficient way possible, especially as the more mature brands in a company's portfolio are susceptible to generic competition and present the reality of impending decreased sales. About $115 billion in total US brand sales is expected to face generic competition from 2014 to 2018, not including the additional loss of sales to biosimilars, according to the Pharmaceutical Research and Manufacturers of America. More than half of those sales ($60 billion) subject to generics are from the portfolios of the Big Pharma, Mid Pharma and Japan Pharma peer sets, groups of leading pharmaceutical companies globally. (See sidebar, Pharma R&D Efficiency: Big, Mid and Japan Pharma Peer Sets.) Compounding that, the pharmaceutical industry traditionally has high failure rates, with only about one in every 10 drugs (across all indications) beginning Phase I likely to be approved by the US Food and Drug Administration. (Also see "Clinical Trial Success Rates Still Dismal, But Certain Sectors Outperform" - In Vivo, 15 June, 2016.)

Big Pharma, or those defined by Informa's Datamonitor Healthcare as having $10 billion or more in annual revenue, excluding generics,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Intelligence

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

In Conversation With Foundation Fighting Blindness

 
• By 

Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.